^
Association details:
| Biomarker: | PIK3CB mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | AZD8186 (PI3Kβ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
Published date:
04/10/2023
Excerpt:
In phase Ib, both MTD and RP2D were determined at paclitaxel 80 mg/m2 and AZD8186 120 mg BID. In phase II, 18 patients were enrolled [PTEN loss (n = 18) and PIK3CB mutation (n = 1)]. The 4-month PFS rate was 18.8% (3 of 16 evaluable patients)...The combination of AZD8186 and paclitaxel was well tolerated...clinical efficacy was observed.
Secondary therapy:
paclitaxel
DOI:
10.1093/oncolo/oyad059
Trial ID:
